Allyx Therapeutics, Inc.
PrivateLast Round
Series A
May 11, 2026
Total Funding Raised
$11.15M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Allyx Therapeutics, Inc. is a biotechnology company developing a first-in-class oral therapy to treat neurodegenerative diseases such as Alzheimer's and Parkinson's.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Allyx Therapeutics, Inc. Comparables
Compare Allyx Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Spinogenix, Inc. | 88% | |
| Annovis Bio, Inc. | 76% | |
| AlzeCure Pharma | 74% |
Allyx Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 11, 2026 | ||||
| Seed Round | Mar 3, 2026 | ||||
| Grant | Oct 15, 2024 | ||||
| Series A | Jun 1, 2021 | ||||
| Early Funding | May 1, 2020 | ||||
Pre Seed | Apr 3, 2019 |
Key People
Founding team and executive leadership
Allyx Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Connecticut Innovations | Series A, Pre Seed, Early Funding |
| NIH RADx | Grant |
| Elm Street Ventures | Series A |
| Canaan Partners | Series A |
| Life Science Angels | Series A |
| Harrington Discovery Institute | Series A |
| Spring Mountain Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 11, 2026
$26.4M raised in an early stage VC round.
- Jun 1, 2021
$7.6M round led by Elm Street Ventures and Bristol Myers Squibb.
Allyx Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Allyx Therapeutics, Inc.'s valuation, stock price, and market status.
Is Allyx Therapeutics, Inc. a public or private company?
Allyx Therapeutics, Inc. is a private company.
What is the current stock price of Allyx Therapeutics, Inc.?
Allyx Therapeutics, Inc. is a private company with no public stock price. No recent secondary market data is available.
How much is Allyx Therapeutics, Inc. worth (valuation)?
Valuation information for Allyx Therapeutics, Inc. is not publicly available.
Can I buy Allyx Therapeutics, Inc. stock?
Allyx Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Allyx Therapeutics, Inc.'s last funding round?
Allyx Therapeutics, Inc.'s most recent funding round was Series A on May 11, 2026.
Who are the main investors in Allyx Therapeutics, Inc.?
Key investors in Allyx Therapeutics, Inc. include Elm Street Ventures, Spring Mountain Capital.
Will Allyx Therapeutics, Inc. IPO soon?
No public IPO plans have been announced for Allyx Therapeutics, Inc..
How can I track Allyx Therapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Allyx Therapeutics, Inc.'s secondary market activity and sign up for updates.